EP2504424A1 - Verfahren zur hepatischen differenzierung von definitiven entodermzellen - Google Patents

Verfahren zur hepatischen differenzierung von definitiven entodermzellen

Info

Publication number
EP2504424A1
EP2504424A1 EP10782300A EP10782300A EP2504424A1 EP 2504424 A1 EP2504424 A1 EP 2504424A1 EP 10782300 A EP10782300 A EP 10782300A EP 10782300 A EP10782300 A EP 10782300A EP 2504424 A1 EP2504424 A1 EP 2504424A1
Authority
EP
European Patent Office
Prior art keywords
cells
hepatic
human
population
hepatocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10782300A
Other languages
English (en)
French (fr)
Inventor
Thomas Touboul
Ludovic Vallier
Anne Weber-Benarous
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Cambridge Enterprise Ltd
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Cambridge Enterprise Ltd filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to EP10782300A priority Critical patent/EP2504424A1/de
Publication of EP2504424A1 publication Critical patent/EP2504424A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Definitions

  • the invention relates to a method for obtaining a population of hepatic progenitor cells, said method comprising a step of culturing definitive endoderm cells with a culture medium stimulating hepatic specification.
  • a culture medium stimulating hepatic specification comprises a retinoic acid receptor (RAR) agonist, an FGF family growth factor and an inhibitor of the activin signaling pathway.
  • RAR retinoic acid receptor
  • liver diseases are becoming one of the most common causes of mortality in developing countries.
  • Orthotopic liver transplantation is currently the only available treatment.
  • an increasing number of patients die while on the liver transplant waiting list due to the shortage of suitable donor livers (Fox and Roy-Chowdhury, 2004).
  • Hepatocyte transplantation recently became an alternative to orthotopic liver transplantation for the treatment of acute failure and life-threatening metabolic liver diseases (Puppi and Dhawan, 2009).
  • this strategy is also restricted by the lack of donors and by the limited number of cells since functional human hepatocytes cannot be expanded in vitro and are difficult to cryopreserve.
  • This group of diseases which targets hepatocytes which represent the dominant liver cells encompasses inherited metabolic disorders (such as Crigler-Najjar Syndrome type I, Glycogen storage disease, Urea cycle defects, familial hypercholesterolemia and tyrosinemia), chronic liver failure as well as acute liver failure, for which hepatocyte transplants can be infused as a bridge to organ transplantation. Therefore exploring other sources of cells to generate hepatic cells with the ability to proliferate in vitro and to express hepatic-specific functions remains a major goal.
  • metabolic disorders such as Crigler-Najjar Syndrome type I, Glycogen storage disease, Urea cycle defects, familial hypercholesterolemia and tyrosinemia
  • hES Human embryonic stem cells
  • hiPS human induced pluripotent stem cells
  • the present invention relates to a method for obtaining a population of hepatic progenitor cells comprising a step of culturing definitive endoderm cells with a culture medium stimulating hepatic specification.
  • the inventors have developed a new culture system to drive differentiation of definitive endoderm cells into hepatic progenitor cells using fully defined culture system devoid of animal products or unknown factors which could impair the use of the resulting cells for cell based therapy. Importantly this approach follows a natural path of development by respecting key stages of liver development which may provide the best approach for generating differentiated cells with native properties.
  • definitive endoderm cells can be differentiated into hepatic progenitors, which can then be matured further into fetal hepatocytes then fully differentiated hepatocytes showing functionality in vitro and in vivo.
  • definitive endoderm cells refers to cells which typically express the following markers Sox17, GSC, Mixl1 , Lhx1 , CXCR4, GATA6, Eomes and Hex. Moreover such definitive endoderm cells do not express extra-embryonic markers such as Sox7 and of neuroectoderm markers such as Sox2.
  • hepatic progenitor cells As used herein, the terms “hepatic progenitor cells”, “hepatoblasts” and “liver progenitors” are used herein interchangeably. They refer to cells that are capable of expressing characteristic biochemical markers, including but not limited to Alpha- fetoprotein (AFP), Albumine (Alb), Cytokeratin 19 (CK19) and Hepatocyte nuclear factor 4alpha (HNF4alpha). Such cells can differentiate into either foetal hepatocytes or into cholangiocytes and express markers of both lineages (i.e. as mentioned above CK19 which is a specific marker of cholangiocytes; HNF4 alpha and AFP which are specific markers of foetal hepatocytes).
  • CK19 which is a specific marker of cholangiocytes
  • HNF4 alpha and AFP which are specific markers of foetal hepatocytes.
  • foetal hepatocytes refers to cells which are engaged in the hepatocytic lineage and which can give rise to mature hepatocytes.
  • foetal hepatocytes express the following markers: Albumin, AFP, CK18, CK8, Apolipoprotein All, Transtherythin, Alpha-1 -antitrypsine, HNF4a, HNF33, ⁇ 1 -integrine, c-Met, RLDL, Cyp3A7, ASGR.
  • the capacity to internalize and to secrete indocyanine green is also typical of hepatocytes Moreover such foetal hepatocytes possess a cuboidal shape.
  • mature hepatocytes or “liver cells” are used herein interchangeably. They refer to cells capable to uptake LDL, to store glycogen and secrete albumin and urea. Typically, mature hepatocytes express the following markers:aldolase B, albumin, Glut 4 , TAT, TO, proteins for detoxification phase I : cytochrome P450, CYP 3A4, CYP 1 A2, CYP 2B6, CYP 2C9, CYP 2E1 , and proteins for detoxification phase II: BilUGT as well as bile acid transporters.
  • cholangiocytes As used herein, the terms “cholangiocytes”, “biliary cells”, “biliary epithelial cells” and “bile duct cells” are used herein interchangeably. They refer to the epithelial cells of the bile duct and contribute to bile secretion via release of phospholipids and biliary salts. Typically, cholangiocytes express the following markers: CK14, CK19, CK 7 and integrin ⁇ 4.
  • pluripotent stem cells refers to undifferentiated cells which have the potential to differentiate into any of the three germs layers: endoderm (interior stomach lining, gastrointestinal tract, the lungs), mesoderm (muscle, bone, blood, urogenital tractus), or ectoderm (epidermal tissues and nervous system). Pluripotent stem cells can thus give rise to any fetal or adult cell type. However, alone they cannot develop into a fetal or adult animal because they lack the potential to contribute to extraembryonic tissue, such as the placenta. Typically, pluripotent stem cells may express the following markers Oct4, Sox2, Nanog, SSEA 3 and 4, TRA 1/81 , see International Stem Cell Initiative recommendations, 2007.
  • embryonic stem cells or “ES cells” or “ESC” refers to cells that are pluripotent and have the ability to form any adult cell.
  • ES cells are derived from fertilized embryos that are less than one week old.
  • human embryonic stem cells may be obtained according a protocol not involving the embryo destruction as described in (Chung et al., 2008; Revazova et al., 2007).
  • induced pluripotent stem cells or "iPS cells” or “iPSCs” refers to a type of pluripotent stem cell artificially derived from a non-pluripotent cell (e.g. an adult somatic cell). Induced pluripotent stem cells are identical to embryonic stem cells in the ability to form any adult cell, but are not derived from an embryo. Typically, an induced pluripotent stem cell may be obtained through the induced ectopic expression of Oct3/4, Sox2, Klf4, and c-Myc genes in any adult somatic cell (e.g. fibroblast).
  • human induced pluripotent stem cells may be obtained according to the protocol as described by (Takahashi et al., 2007; Yu et al., 2007) or else by any other protocol in which one or the other agents used for reprogramming cells in these original protocols are replaced by any gene or protein acting on or transferred to the somatic cells at the origin of the iPS lines.
  • adult somatic cells are transduced with viral vectors, such as retroviruses, which comprise Oct3/4, Sox2, Klf4, and c-Myc genes.
  • multipotent stem cells refers to a stem cell that has the potential to give rise to cells from multiple, but a limited number of lineages.
  • adult human stem cells that can be used in the methods of the present invention include but are not limited to, multipotent mesenchymal stromal cells (MSCs), adult multilineage inducible (MIAMI) cells (D'lppolito et al., 2004; Reyes et al., 2002) (Reyes et al., 2002), MAPC (also known as MPC), cord blood derived stem cells (Kogler et al., 2004), and mesoangioblasts (Dellavalle et al., 2007; Sampaolesi et al., 2006).
  • MSCs multipotent mesenchymal stromal cells
  • MIAMI adult multilineage inducible
  • MAPC also known as MPC
  • cord blood derived stem cells Kogler et al., 2004
  • mesoangioblasts Dellavalle et al., 2007; Sampaolesi et al., 2006).
  • multipotent mesenchymal stromal cells As used herein, the terms “multipotent mesenchymal stromal cells”, “mesenchymal stem cells” or “MSCs” are used herein interchangeably and refer to cells which are isolated mainly from bone marrow (Jiang et al., 2002) and adipose tissue (Aurich et al., 2009) (or fat tissue) but which have also been identified in other tissues such as synovium, periosteum or placenta. These cells are characterised by their property to adhere to plastic, their phenotype and their ability to differentiate into three different lineages (chondrocytes, osteoblasts and adipocytes).
  • culture medium refers to any medium capable of supporting the growth and the differentiation of definitive endoderm cells into hepatic progenitor cells.
  • Preferred media formulations that will support the growth and the differentiation of definitive endoderm cells into hepatic progenitor cells include chemically defined medium (CDM).
  • chemically defined medium refers to a nutritive solution for culturing cells which contains only specified components, preferably components of known chemical structure.
  • a chemically defined medium is a serum-free and feeder-free medium.
  • feeder-free refers to a culture medium containing no added serum.
  • feeder-free refers to culture medium containing no added feeder cells. The term feeder-free encompasses, inter alia, situations where definitive endoderm are passaged from a culture with feeders into a culture medium without added feeders even if some of the feeders from the first culture are present in the second culture.
  • a chemically defined medium is devoid of components derived from non-human animals, such as Foetal Bovine Serum (FBS), Bovine Serum Albumin (BSA), and animal feeder cells such mouse feeder cells.
  • FBS Foetal Bovine Serum
  • BSA Bovine Serum Albumin
  • animal feeder cells such mouse feeder cells.
  • Suitable CDM include humanised Johansson and Wiles CDM.
  • Humanised Johansson and Wiles CDM is described in (Johansson and Wiles, 1995) and is supplemented with insulin, transferrin and defined lipids to which may be added polyvinyl alcohol (PVA) as substitute for Bovine Serum Albumin (BSA).
  • PVA polyvinyl alcohol
  • BSA Bovine Serum Albumin
  • CDM-PVA refers to the humanised chemically defined medium of Johansson and Wiles comprising polyvinyl alcohol (PVA) instead of bovine or human serum albumin.
  • an appropriate CDM according to the invention may consist in 50 % IMDM (e.g. from Invitrogen, Cergy, France) and 50% F12 NUT MIX (e.g. from Invitrogen), supplemented with 7 ⁇ g/ml of insulin (e.g. from Roche, Sandhofer, Germany), 15 ⁇ g/ml of transferrin (e.g. from Roche), 450 ⁇ of monothioglycerol (e.g. from Sigma-Aldrich, St Quentin, France) and 1 mg /ml of Polyvinyl Alcohol (PVA; e.g. from Sigma).
  • PVA Polyvinyl Alcohol
  • culture medium stimulating hepatic specification refers to a culture medium that is capable of inducing the expression of hepatic markers such as Alpha-fetoprotein (AFP), Albumin (Alb) and Hepatocyte nuclear factor 4a (HNF4alpha).
  • AFP Alpha-fetoprotein
  • Alb Albumin
  • HNF4alpha Hepatocyte nuclear factor 4a
  • the term "marker” refers to a protein, glycoprotein, or other molecule expressed on the surface of a cell or into a cell, and which can be used to help identify the cell.
  • a marker can generally be detected by conventional methods. Specific, non-limiting examples of methods that can be used for the detection of a cell surface marker are immunocytochemistry, fluorescence activated cell sorting (FACS), and enzymatic analysis.
  • the term "nearly homogenous population” refers to a population of cells wherein the majority (e.g., at least about 60%, preferably at least about 70%, more preferably at least about 80%) of the total number of cells have the specified characteristics of the hepatic progenitor cells of interest.
  • a “receptor” or “receptor molecule” is a soluble or membrane bound/associated protein or glycoprotein comprising one or more domains to which a ligand binds to form a receptor-ligand complex. By binding the ligand, which may be an agonist or an antagonist, the receptor is activated or inactivated and may initiate or block pathway signalling.
  • a “receptor agonist” is a natural or synthetic compound which binds the receptor to form a receptor-agonist complex by activating said receptor and receptor-agonist complex, respectively, initiating a pathway signaling and further biological processes.
  • receptor antagonist or “receptor inhibitor” is meant a natural or synthetic compound that has a biological effect opposite to that of a receptor agonist.
  • the term is used indifferently to denote a “true” antagonist and an inverse agonist of a receptor.
  • a "true” receptor antagonist is a compound which binds the receptor and blocks the biological activation of the receptor, and thereby the action of the receptor agonist, for example, by competing with the agonist for said receptor.
  • An inverse agonist is a compound which binds to the same receptor as the agonist but exerts the opposite effect. Inverse agonists have the ability to decrease the constitutive level of receptor activation in the absence of an agonist.
  • pathologies refers to any disease or condition associated with hepatic damage.
  • pathology associated with hepatic damage refers to any disease or clinical condition characterized by hepatic damage, injury, dysfunction, defect, or abnormality.
  • the term encompasses, for example, injuries, degenerative diseases and genetic diseases.
  • pathologies of interest are genetic diseases including metabolic diseases, acute liver failure, chronic hepatitis
  • the term "subject” refers to a mammal, preferably a human being, that can suffer from pathology associated with hepatic damage, but may or may not have the pathology.
  • treating refers to a method that is aimed at delaying or preventing the onset of a pathology, at reversing, alleviating, inhibiting, slowing down or stopping the progression, aggravation or deterioration of the symptoms of the pathology, at bringing about ameliorations of the symptoms of the pathology, and/or at curing the pathology.
  • the present invention relates to a method for obtaining a population of hepatic progenitor cells comprising a step of culturing definitive endoderm cells with a culture medium stimulating hepatic specification.
  • said definitive endoderm cells are obtained from the differentiation of pluripotent or multipotent stem cells.
  • the definitive endoderm cells are human definitive endoderm cells.
  • said human definitive endoderm cells are obtained from pluripotent stem cells, such as human embryonic stem cells (ES) or human induced pluripotent cells (iPS), according to a method described in the international patent application WO 2008/056166.
  • the definitive endoderm cells may be obtained by culturing ES or iPS for 1 to 4 days, preferably 2 days, in CDM-PVA supplemented with Activin 5-20 ng/ml, preferably 10 ng/ml, and FGF2 1 -50 ng/ml, preferably 12 ng/ml; then for 1 to 5 days, preferably 3 days, in CDM-PVA supplemented with Activin 1 -200 ng/ml, preferably 100 ng/ml, FGF2 1 -100 ng/ml, preferably 20 ng/ml, BMP4 1 -100 ng/ml, preferably 10 ng/ml, and LY294002 10 ⁇ .
  • said human definitive endoderm cells are obtained from multipotent stem cells such as umbilical cord blood stem cells.
  • the pluripotent or multipotent stem cells contain a genetic mutation responsible for a hepatic genetic disease.
  • the population of hepatic progenitors cells obtained from said pluripotent or multipotent cells also contains said mutation and can therefore provide a good cellular model of the disease.
  • the culture medium stimulating hepatic specification comprises an RAR agonist.
  • RAR agonist refers to any compound, natural or synthetic, which results in an increased activation of the retinoic acid receptor.
  • the retinoid receptors are indeed classified into two families, the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs), each consisting of three distinct subtypes. Each subtype of the RAR gene family encodes a variable number of isoforms arising from differential splicing of two primary RNA transcripts. All-trans retinoic acid (ATRA) is the physiological hormone for the retinoic acid receptors and binds with approximately equal affinity to all the three RAR subtypes. ATRA does not bind to the RXR receptors and therefore is a selective RAR agonist.
  • RARs retinoic acid receptors
  • RXRs retinoid X receptors
  • RAR selective agonist it is meant a compound which activates RAR but which exhibits little or no activation of, or actually inhibits, RXR.
  • selective may denote that the affinity of the agonist for the retinoic acid receptors (RAR) is at least 25-fold, preferably 50-fold, more preferably 100-fold higher than the affinity for the retinoid X receptors (RXR).
  • Selectivity of an agonist for RAR may be assayed for instance by determining is said compound induces growth inhibition of a human head and neck squamous cell carcinoma (HNSCC) cell line, such as UMSCC10B, UMSCC1 1 B, UMSCC14B, UMSCC17A, UMSCC17B, UMSCC22A, and UMSCC22B (Krause et al., 1981 ), UMSCC38 and 183A (Grenman et al., 1991 ), MDA886Ln (Sacks et al., 1989), 1483 (Sacks et al., 1988), SqCC/Y1 (Reiss et al., 1985), TR146 (Rupniak et al., 1985).
  • HNSCC human head and neck squamous cell carcinoma
  • RAR-selective retinoids were active in inhibiting the growth of most of these HNSCC cell lines whereas RXR-selective agonists exhibited weak or no inhibitory effect on all these cell lines (Sun et al., 2000).
  • RAR or RXR selectivity may also be assayed by measuring receptor binding, transactivation activity and the ability to induce RXR homodimer formation as described in (38).
  • the RAR agonist is a selective RAR agonist.
  • the selective RAR agonists are selected in the group consisting of all-trans retinoic acid(RA), pan RAR agonists (i.e. compounds which activates the alpha, beta, and gamma isotypes of RAR) LGD 1550, E6060, selective RAR agonists such as CD336 (Am 580), AGN193312, Am555S, Am80, CD2314, AGN193174, LE540, CD437, CD666, CD2325, SR1 1254, SR1 1363, SR1 1364, AGN193078, TTNN (Ro 19-0645), CD270, CD271 , CD2665, SR3985, AGN193273, Ch55, 2AGN190521 , CD2366, AGN193109, Re80 (Sun et al., 1997).
  • RA all-trans retinoic acid
  • pan RAR agonists i.e. compounds which activates the alpha, beta, and gamma
  • the RAR agonist may also be Ro 40-6976, Ro 13- 7410 (TTNPB), Ro 1 1 -0874, Ro 04-3780 (13-cis-RA), Ro 1 1 -4824 (4-oxo-RA), Ro 1 1 - 1813, Ro 08-8717, Ro 10-0191 , Ro 10-2655 (4-hydroxy-RA) and Ro 1 1 -0976 (Crettaz et al., 1990), or Ro 40-6055 and Ro 41 -5253 (Horn et al., 1996) or CD 2019.
  • the RAR agonist is all-trans retinoic acid (ATRA) which is the acid form of vitamin A.
  • ATRA all-trans retinoic acid
  • the concentration of the RAR agonist in the culture medium stimulating hepatic specification may be from 10 ⁇ 8 M to 10 ⁇ 6 M, preferably about 10 ⁇ 7 M.
  • the culture medium stimulating hepatic specification further comprises an FGF family growth factor and an inhibitor of the activin/nodal signaling pathway.
  • FGF family growth factor refers to any naturally occurring substance (e.g. a protein) capable of stimulating cellular growth, proliferation and cellular differentiation by binding to one fibroblast growth factor receptor (FGFR). By binding to one FGFR, the substance increases for example the tyrosine phosphorylation of said receptor.
  • FGFR fibroblast growth factor receptor
  • the FGF family growth factor is selected from the group consisting of FGF7 (also known KGF), FGF10 and FGF22 which constitutes a subfamily (FGF7 subfamily (Yeh et al., 2003)) among FGF family members since these three growth factors preferably bind the keratinocyte growth factor receptor (KGFR) and the fibroblast growth factor receptor expressed by epithelial cells (FGFR2-llb, and FGFR1 B for FGF10 only).
  • FGF7 also known KGF
  • FGF10 and FGF22 which constitutes a subfamily (FGF7 subfamily (Yeh et al., 2003)) among FGF family members since these three growth factors preferably bind the keratinocyte growth factor receptor (KGFR) and the fibroblast growth factor receptor expressed by epithelial cells (FGFR2-llb, and FGFR1 B for FGF10 only).
  • the FGF family growth factor is substance having a FGF10-like activity, e.g. a FGF10 mimetic.
  • a FGF10 mimetic e.g. a FGF10 mimetic.
  • Such a substance may be identified by screening compounds for their capacity to restore FGF10 signaling in a cell knock-out for the receptor FGFR2b, or to activate FGFR2b at the surface of a cell contacted with an inhibitor of FGFR2b such as LPS, Pam 3 Cys-Ser-(Lys) 4 and Sprouty (Spry) proteins.
  • the FGF family growth factor is FGF10.
  • FGF10 can be purchased from AutogenBioclear.
  • the FGF family growth factor, and in particular FGF10 is added to the culture medium of the invention in a concentration ranging from 1 to 200 ng/ml, preferably 20 to 100 ng/ml and preferably at about 50 ng/ml.
  • inhibitor of the activin/nodal signaling pathway refers to any compound, natural or synthetic, which results in a decreased activation of the activin/nodal signaling pathway, which is the series of molecular signals generated as a consequence of any member of the activin family binding to a cell surface receptor.
  • an inhibitor of the activin/nodal signaling pathway provokes a decrease in the levels of phosphorylation of the protein Smad 2 (Shi and Massague, 2003).
  • the inhibitor of the activin/nodal signaling pathway may be an activin/nodal antagonist or a molecule which inhibits any downstream step of the activin/nodal signaling pathway.
  • the inhibitor of the activin/nodal signaling may be a natural or a synthetic compound.
  • the inhibitor of the activin/nodal signaling pathway is a protein, it may be a purified protein or a recombinant protein or a synthetic protein.
  • the inhibitor of the activin/nodal signaling pathway is selected from the group consisting of SB431542, Lefty-A, Cerberus, Coco (accession number GenBank 22749329 or NCBI NP_689867.1 ) and derivatives of Lefty-A and Cerberus which inhibit the activin signaling pathway.
  • Cerberus examples include truncated Cerberus (Cerb-S) (Smith et al, 2008), fragments of human Cerberus (accession number NCBI NP 005445) which begin anywhere from residues 106-1 19 (inclusive) at the N-terminus and end anywhere after residue 241 , and fragments of murin Cerberus (accession number NCBI NP 034017) which begin anywhere from residues 106-1 19 (inclusive) at the N-terminus and end anywhere after residue 241 .
  • the inhibitor of the activin /nodal signaling pathway is 4-(5-Benzol[1 ,3]dioxol-5-yl-4-pyrlidn-2-yl-1 H-imidazol-2-yl)-benzamide hydrate also known as SB431542 which can be purchased from Tocris and Sigma.
  • SB431542 is added to the culture medium of the invention in a concentration ranging from 1 to 100 ⁇ , preferably 5 to 25 ⁇ , still preferably at about 10 ⁇ .
  • the culture medium stimulating hepatic specification comprises
  • the culture medium stimulating hepatic specification may comprise as a base medium CMD- PVA consisting of 50 % IMDM and 50% F12 NUT, insulin 7 g/ml, transferring 15 ⁇ g/ml, monothioglycerol 450 ⁇ and Polyvinyl Alcohol (PVA) 1 mg /ml, supplemented with a RAR agonist, a FGF family growth factor, and an inhibitor of the activin/nodal signaling pathway, as described above.
  • CMD- PVA consisting of 50 % IMDM and 50% F12 NUT, insulin 7 g/ml, transferring 15 ⁇ g/ml, monothioglycerol 450 ⁇ and Polyvinyl Alcohol (PVA) 1 mg /ml, supplemented with a RAR agonist, a FGF family growth factor, and an inhibitor of the activin/nodal signaling pathway, as described above.
  • the culture medium stimulating hepatic specification comprises:
  • - 10 "8 M to 10 ⁇ 6 M preferably about 10 ⁇ 7 M of a RAR agonist, in particular ATRA; - 1 to 200 ng/ml, preferably 20 to 100 ng/ml, still preferably about 50 ng/ml of a
  • FGF family growth factor selected from the group consisting of FGF7, FGF10 and FGF22, preferably FGF10;
  • the culture medium stimulating hepatic specification comprises a base medium CMD-PVA supplemented with :
  • - 10 "8 M to 10 ⁇ 6 M preferably about 10 ⁇ 7 M of a RAR agonist, in particular ATRA
  • - 1 to 200 ng/ml preferably 20 to 100 ng/ml, still preferably about 50 ng/ml of a FGF family growth factor selected from the group consisting of FGF7, FGF10 and FGF22, preferably FGF10; and
  • the step of culturing definitive endoderm cells with the culture medium stimulating hepatic specification shall be carried out for the necessary time required for the hepatic specification of definitive endoderm cells.
  • the duration of this culture step may be determined easily by one of skill in the art. For instance, during the culture the person skilled in the art can monitor the cultured cells for the absence of expression of markers specifically expressed in definitive endoderm cells (e.g. Sox17, GSC, MixM , Lhx1 , CXCR4, GATA6, Eomes and Hex) and/or for the expression of markers specifically expressed by hepatic progenitor cells (e.g.
  • AFP Alpha-fetoprotein
  • Albumine Albumine
  • CK19 Cytokeratin 19
  • HNF4alpha Hepatocyte nuclear factor 4alpha
  • the culture of definitive endoderm cells with said medium stimulating hepatic specification may be carried out for at least 2 days, preferably at least 3 days, even more preferably at least 5 days.
  • the culture of definitive endoderm cells with said medium stimulating hepatic specification is carried out for 2 to 5 days, in particular for 2 or 3 days.
  • the culture medium of the invention has to be renewed, partly or totally, at regular intervals.
  • the culture medium of the invention can be replaced with fresh culture medium of the invention every other day.
  • the culture may be carried out in a support (plate, flask, etc) coated with a protein, peptide or molecule favouring cell adhesion, such as fibronectin, collagen or gelatine.
  • a support plate, flask, etc
  • a protein, peptide or molecule favouring cell adhesion such as fibronectin, collagen or gelatine.
  • the definitive endoderm cells are previously cultured with an FGF family growth factor before culturing them with a culture medium stimulating hepatic specification.
  • definitive endoderm cells are cultured in a first step a) with an FGF family growth factor, then in a second step b) the cells cultured in step a) are cultured with said culture medium stimulating hepatic specification.
  • the FGF family growth factor is FGF10.
  • FGF10 is added to the culture medium of the invention in a concentration ranging from 1 to 100 ng/ml, preferably at about 50 ng/ml.
  • the culture of definitive endoderm cells with said FGF family growth factor may be carried out for at least 2 days, preferably at least 3 days, even more preferably at least 5 days.
  • the culture of definitive endoderm cells with said FGF family growth factor may be carried out for 2 to 10 days, preferably 2 to 5 days, still preferably for 3 days.
  • the culture medium of the invention may be renewed, partly or totally, at regular intervals (e.g. every day).
  • the hepatic progenitor cells produced by the above method may be isolated and/or purified using any suitable method, for example flow cytometry.
  • hepatic progenitor cells may, for example, be expanded or propagated in culture or used in clinical applications.
  • hepatic progenitor cells may be further genetically modified with a nucleic acid of interest.
  • the modified hepatic progenitor cells may be useful as vector for delivering acid nucleic.
  • hepatic progenitor cells may be further differentiated.
  • the population of hepatic progenitor cells derived from definitive endoderm cells of the invention may be thus suitable for obtaining foetal hepatocytes.
  • a second aspect of the invention relates to a method for obtaining a population of foetal hepatocytes comprising the steps of:
  • the step of differentiating the population of hepatic progenitor cells into foetal hepatocytes is carried out by culturing said hepatic progenitor cells with a culture medium comprising an FGF family growth factor, an agonist of the EGF signaling pathway and an agonist of the HGF signaling pathway.
  • FGF family growth factor refers to any refers to any naturally occurring substance (e.g. a protein) capable of stimulating cellular growth, proliferation and cellular differentiation by binding to one fibroblast growth factor receptor (FGFR). By binding to one FGFR, the substance increases for example the tyrosine phosphorylation of said receptor.
  • FGFR fibroblast growth factor receptor
  • the FGF family growth factor is FGF4 (also known as heparin secretory transforming protein 1 or Kaposi sarcoma oncogene).
  • FGF4 is added to the culture medium of the invention in a concentration ranging from 1 to 100 ng/ml, preferably 1 to 50 ng/ml, still preferably at about 30 ng/ml.
  • FGF4 can be purchased from Peprotech.
  • agonist of the EGF signaling pathway refers to any compound, natural or synthetic, which results in an increased activation of the epidermal growth factor receptor (EGFR) which is the cell membrane receptor for EGF.
  • EGFR epidermal growth factor receptor
  • the EGFR also binds other ligands that contain amino acid sequences classified as the EGF-like motif.
  • the EGFR is also known as the ErbB-1 receptor and belongs to the type I family of receptor tyrosine kinases.
  • a method for designing agonists to EGF receptor is for example described in international patent WO 99/62955.
  • the agonist of the EGF signaling pathway is selected from the group consisting of epidermal growth factor (EGF), heparin-binding EGF-like growth factor (HB-EGF), vascular endothelial growth factor (VEGF) and Immunoglobulin-Binding Protein (IGBP).
  • EGF epidermal growth factor
  • HB-EGF heparin-binding EGF-like growth factor
  • VEGF vascular endothelial growth factor
  • IGBP Immunoglobulin-Binding Protein
  • the agonist of the EGF signaling pathway is EGF.
  • EGF is added to the culture medium of the invention at a concentration ranging from 1 to 100 ng/ml, preferably at about 50 ng/ml.
  • EGF can be purchased from Peprotech.
  • agonist of the HGF signaling pathway refers to any compound, natural or synthetic, which is capable of, directly or indirectly, substantially inducing, promoting or enhancing HGF biological activity or HGF receptor activation.
  • HGF biological activity may, for example, be determined in an in vitro or in vivo assay of hepatocyte growth promotion as described in US patent 6,099,841 .
  • the agonist of the HGF signaling pathway may be hepatocyte growth factor (HGF) (Michieli et al., 2002) or any susbstance capable of activating HGF pathway, such as a drug, a synthetic or natural analog of HGF, for instance a truncated form of HGF.
  • HGF hepatocyte growth factor
  • the agonist may be magic-factor 1 , a partial agonist of the Met tyrosine kinase, the high affinity receptor of HGF (39)
  • the agonist of the HGF signaling pathway is HGF.
  • HGF is added to the culture medium of the invention in a concentration ranging from 1 to 100 ng/ml, preferably at about 50 ng/ml.
  • HGF can be purchased from Peprotech.
  • the step of culturing cells with the culture medium stimulating differentiation of hepatic progenitor cells shall be carried out for the necessary time required for the production of hepatic progenitor cells.
  • the duration of this culture step may be determined easily by one of skill in the art. For instance, during the culture the person skilled in the art can monitor the cultured cells for the absence of expression of markers only expressed by hepatic progenitor cells (e.g. Cytokeratin 19) and/or for the expression of markers specifically expressed by foetal hepatocytes (e.g.
  • the culture of definitive endoderm cells with said medium of the invention may be carried out for at least 3 days, preferably at least 7 days, even more preferably at least 15 days.
  • the culture medium of the invention can be renewed, partly or totally, at regular intervals.
  • the culture medium of the invention can be replaced with fresh culture medium of the invention every other day, for 15 days.
  • the foetal hepatocytes produced by the above method may be isolated and/or purified using any suitable method, for example FACS.
  • the foetal hepatocytes cells may, for example, be expanded or propagated in culture or used in clinical applications. In some embodiments, foetal hepatocytes may be further differentiated into mature hepatocytes.
  • the population of foetal hepatocytes of the invention may be thus suitable for obtaining mature hepatocytes.
  • the population of hepatic progenitor cells and/or foetal hepatocytes derived from definitive endoderm cells obtained according to the method of the invention may be then suitable for hepatic therapy and/or hepatic reconstruction or regeneration.
  • a pharmaceutical composition comprising a population of hepatic progenitor cells of the invention and optionally a pharmaceutically acceptable carrier or excipient.
  • a pharmaceutical composition may further comprise at least one biologically active substance or bioactive factor.
  • the term "pharmaceutically acceptable carrier or excipient” refers to a carrier medium which does not interfere with the effectiveness of the biological activity of the progenitor cells, and which is not excessively toxic to the host at the concentrations at which it is administered.
  • suitable pharmaceutically acceptable carriers or excipients include, but are not limited to, water, salt solution (e.g., Ringer's solution), oils, gelatines, carbohydrates (e.g., lactose, amylase or starch), fatty acid esters, hydroxymethylcellulose, and polyvinyl pyroline.
  • Pharmaceutical compositions may be formulated as liquids, semi-liquids (e.g., gels, alginate beads) or solids (e.g., matrix, lattices, scaffolds, and the like).
  • biologically active substance or bioactive factor refers to any molecule or compound the presence of which in a pharmaceutical composition of the invention is beneficial to the subject receiving the composition.
  • biologically active substances or bioactive factors suitable for use in the practice of the present invention may be found in a wide variety of families of bioactive molecules and compounds.
  • a biologically active substance or bioactive factor useful in the context of the present invention may be selected from antiinflammatory agents, anti-apoptotic agents, immunosuppressive or immunomodulatory agents, antioxidants, growth factors, and drugs.
  • a related aspect of the invention relates to a method for treating a subject suffering from a hepatic pathology, said method comprising a step of administering to the subject an efficient amount of a population of hepatic progenitor cells derived from definitive endoderm cells (or a pharmaceutical composition thereof).
  • the hepatic pathology which may be treated is selected in the group consisting of inherited metabolic disorders (such as Crigler-Najjar Syndrome type I, glucogenosis 1 a, Urea cycle defects, familial hypercholesterolemia, tyrosinemia and Wilson's Disease), chronic or acute liver failure which may be caused by viral infection (in particular infection with HBV or HCV), toxic (alcohol) and drugs, or autoimmune disorder (Autoimmune Chronic Hepatitis, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis).
  • inherited metabolic disorders such as Crigler-Najjar Syndrome type I, glucogenosis 1 a, Urea cycle defects, familial hypercholesterolemia, tyrosinemia and Wilson's Disease
  • chronic or acute liver failure which may be caused by viral infection (in particular infection with HBV or HCV), toxic (alcohol) and drugs
  • autoimmune disorder Autoimmune Chronic Hepatitis, Primary Biliary Cirrhosis, Primary Scleros
  • the term "efficient amount” refers to any amount of a population of hepatic progenitor cells derived from definitive endoderm cells (or a pharmaceutical composition thereof) that is sufficient to achieve the intended purpose.
  • the population of hepatic progenitor cells derived from definitive endoderm cells (or a pharmaceutical composition thereof) of the invention may be administered to a subject using any suitable method.
  • the hepatic progenitor cells derived from definitive endoderm cells of the invention may be implanted alone or in combination with other cells, and/or in combination with other biologically active factors or reagents, and/or drugs. As will be appreciated by those skilled in the art, these other cells, biologically active factors, reagents, and drugs may be administered simultaneously or sequentially with the cells of the invention.
  • a treatment according to the present invention further comprises pharmacologically immunosuppressing the subject prior to initiating the cell- based treatment.
  • pharmacologically immunosuppressing Methods for the systemic or local immunosuppression of a subject are well known in the art.
  • Effective dosages and administration regimens can be readily determined by good medical practice based on the nature of the pathology of the subject, and will depend on a number of factors including, but not limited to, the extent of the symptoms of the pathology and extent of damage or degeneration of the tissue or organ of interest, and characteristics of the subject (e.g., age, body weight, gender, general health, and the like).
  • the different population of cells of the present invention may also have others uses. These uses include, but are not limited to, use for modelling injuries or pathologies associated with hepatic damage and for screening compounds in rodents.
  • said population of cells may also be used for a variety of in vitro and in vivo tests. In particular but in non limiting way, they find use in the evaluation of hepatotoxicity of compounds such as pharmaceutical candidate compounds.
  • a further aspect of the invention relates to a method for screening compounds having a hepatoprotective or hepatotoxic effect wherein said method comprises the steps of:
  • a culturing a population of hepatic progenitor cells, a population of foetal hepatocytes or a population of mature hepatocytes according to the invention in the presence of a test compound, and
  • step b comparing the survival of the cells of step a) to that of a population of said cells as defined above cultured in the absence of said test compound.
  • hepatotoxic refers to a compound which provokes a decrease in the survival of hepatic progenitor cells or hepatocytes.
  • a compound is deemed to have a hepatotoxic effect if the number of viable cells cultured in the presence of said compound is lower than the number of viable cells cultured in the absence of said compound.
  • hepatoprotective refers to a compound which results in an increase survival of hepatic progenitor cells or neurons.
  • a compound is deemed to have a hepatoprotective effect if the number of viable cells cultured in the presence of said compound is higher than the number of viable cells cultured in the absence of said compound.
  • the hepatoprotective effect can be assayed in the absence of hepatotrophic factors.
  • the hepatoprotective effect can be assayed in the presence of a known hepatotoxic drug.
  • Known hepatotoxic drugs include, but are not limited to amiodarone, methotrexate, nitrofurantoin.
  • hepatic progenitor cells and/or foetal hepatocytes which may be derived from human ES or iPS further makes it possible to design in vitro and in vivo models of human liver diseases and hepatotropic viruses, in particular hepatitis B or C. More specifically an in vivo model of human liver diseases and hepatotropic viruses may be provided by repopulating the liver of a non-human mammal with human hepatic progenitors and/or foetal hepatocytes.
  • the invention further relates to the use of human hepatic progenitor cells and/or human foetal hepatocytes obtained or obtainable by a method according to the invention for producing a non-human mammalian host which comprises functional human hepatocytes.
  • a suitable method to produce a chimeric non-human mammal which comprises functional human hepatocytes may comprise the step consisting of injecting into the liver of said non-human mammal human hepatic progenitor cells and/or human foetal hepatocytes according to the invention.
  • the non-human mammal may receive an antimacrophage treatment to control non adaptive defense. This may be carried out for instance by administering dichloromethylene diphosphonate, e.g. by intraperitoneal injection of liposome-encapsulated dichloromethylene diphosphonate.
  • the invention further relates to a chimeric non-human mammal which comprises functional human hepatocytes obtained or obtainable by the method of the invention.
  • the non-human mammal of the invention may be any non-primate mammal into which human hepatocytes may be introduced and maintained. This includes, but is not limited to, horses, sheep, cows, cats, dogs, rats, hamsters, rabbits, gerbils, guinea pigs, and mice.
  • the host animal is a rodent, still preferably a mouse. It can also be non human primate (Macacus).
  • the non-human mammal may be in particular an immunocompromised mammal which will generally be incapable of mounting a full immune response against the xenogeneic cells (human hepatocytes).
  • Immunocompromised mammalian hosts suitable for implantation exist or can be created, e.g., by administration of one or more compounds (e.g., cyclosporin) or due to a genetic defect which results e.g. in an inability to undergo germline DNA rearrangement at the loci encoding immunoglobulins and T-cell antigen receptors.
  • Functionality of the human hepatocytes can be monitored by looking at surrogate markers for hepatocyte activity, including physiologic products of human hepatocytes distinguishable from their non-human mammalian, in particular murine, analogs by immunologic or quantitative criteria, e.g., expression of human serum albumin, or expression of C-reactive protein in response to IL-6, etc. These markers can be used to determine the presence of cells without sacrifice of the recipient.
  • FIGURE The chimeric non-human mammal which comprises functional human hepatocytes may be used in particular as an in vivo model of human hepatitis B infection.
  • the invention will be further illustrated by the following figures and examples. However, these examples and figures should not be interpreted in any way as limiting the scope of the present invention.
  • FIGURE
  • Figure 1 represents a scheme of the method according to the invention for differentiating human pluripotent or multipotent stem cells into hepatic progenitors using chemically defined medium.
  • DE cells were cultured in CDM-PVA during three days in presence of FGF10 (50 ng/ml, Autogenbioclear, Nottingham, UK) and then the resulting cells were grown in presence of Retinoic Acid (10 ⁇ 7 M, Sigma), SB431542 (10 ⁇ , Tocris, Bristol, UK) and FGF10 (50 ng/ml, Autogenbioclear).
  • FGF10 50 ng/ml, Autogenbioclear, Nottingham, UK
  • Retinoic Acid 10 ⁇ 7 M, Sigma
  • SB431542 10 ⁇ , Tocris, Bristol, UK
  • FGF10 50 ng/ml, Autogenbioclear
  • hepatic progenitors were grown in presence of FGF4 (30 ng/ml, Peprotech, Neuilly-sur- Seine, France), HGF (50 ng ml-1 , Peprotech) and EGF (50 ng ml-1 , Peprotech) for 3 to 15 days to drive their differentiation into hepatocytes.
  • FGF4 (30 ng/ml, Peprotech, Neuilly-sur- Seine, France
  • HGF 50 ng ml-1 , Peprotech
  • EGF 50 ng ml-1 , Peprotech
  • RNAs were extracted from cells using the RNeasy Mino Kit (Quiagen, Courtaboeuf, France). Each sample was treated with RNAse-free DNAse (Quiagen). For each sample 0.6 ⁇ g of RNA was reverse transcribed using Superscript II Reverse Transcriptase (Invitrogen). PCR amplification was performed using the GoTaq Flexi DNA Polymerase (Promega, Charbonni, France). The primers used and conditions are described in Table 1 .
  • Real Time RT-PCR was performed using a Stratagen Mw3005P and the mixture was prepared as described by the manufacturer (SensiMiX Protocol Quantace, London, UK) then denatured at 94°C for 30 seconds, 60 ⁇ € for 30 seconds, and 72°C for 30 seconds followed by final extension at 72 ⁇ ⁇ for 10 minutes after completion of 40 cycles.
  • the primers used for the Quantitative PCR are described in Table 2. Each reaction was performed in duplicate and normalized to PBGD on the same run. The results are presented as the mean of three independent experiments and error bars indicate standard deviation.
  • Antisense ACA CTC GGA CCA CAT CCT TC (SEQ ID NO:30)
  • Sox 17 Sense GAT ACG CCA GTG ACG ACC AGA (SEQ ID NO:31 )
  • Antisense ATC TTG CTC AAC TCG GCG TT (SEQ ID NO:32)
  • HNF3b Sense GGG AGC GGT GAA GAT GGA (SEQ ID NO:33)
  • HNF1 b Sense TCA CAG ATA CCA GCA GCA TCA GT (SEQ ID NO:35)
  • Antisense GGG CAT CAC CAG GCT TGT A (SEQ ID NO:36)
  • HNF4 Sense CAT GGC CAA GAT TGA AAC CT (SEQ ID NO:37)
  • HNF6 Sense CGC TCC GCT TAG CAG CAT (SEQ ID NO:39)
  • Antisense AGA AGC GCA GTT GCT TGG (SEQ ID NO:42)
  • Antisense AAAGGCAATCAACACCAAGG (SEQ ID NO:46)
  • Sox7 Sense CAT GCA GGA CTA CCC CAA CT (SEQ ID NO:47)
  • Antisense GCT ACA GTG GAG AGG GCT TG (SEQ ID NO:48)
  • hHex Sense GCGAGAGACAGGTCAAAACC (SEQ ID NO:49)
  • Antisense AG G G CG A AC ATTG AG AG CTA (SEQ ID NO:50)
  • E-Cadherin Sense GCT GGA GAT TAA TCC GGA CA (SEQ ID NO:51 )
  • Antisense ACC TGA GGC I I I GGA TTC CT (SEQ ID NO:52)
  • Cells were harvested by dissociation for 5 min at 37 ⁇ C with 0.2 mg/ml EDTA (Sigma) and 1 mg/ml BSA fraction V (Sigma) in PBS washed and resuspended in PBS+3% FBS. Cells were incubated at 4°C with primaries antibodies rabbit anti-human c- met (1 :25) (Tebu Bio), or rabbit anti-human ASGr (1 :25) (Abeam Cambridge, UK), rabbit anti-human rLDL (1 :20) (Abeam) or a CD-49f FITC-conjugated antibody (1 :20) (BD Pharmingen, Brumath, France). After 3 washes, cells were incubated with an antibody PE-conjugated goat anti rabbit (1 :100). Cells were then analysed using a FACS-Calibur (BD Biosciences).
  • Glycogen storage was assayed by the Periodate-Schiff technique according to McManus.
  • Uptake of LDL was performed using Dil-Ac-LDL staining kit (Biomedical Technologies, Stoughton, MA) and the assay was performed according to the manufacturer's instructions.
  • Dil-Ac-LDL staining kit Biomedical Technologies, Stoughton, MA
  • the assay was performed according to the manufacturer's instructions.
  • cells were fixed in 4% paraformaldehyde and then further assayed by immunofluorescence as described above.
  • the Indocyanine green (ICG) uptake test was performed by incubation of the cells with 1 mg/ml ICG for 60min. Cells were then washed in medium and release of ICG was evaluated 16 hours later.
  • CYP3A7 activity was measured using the P450-Glo assays kit (Promega) according manufacturer recommendation. Cytochrome activity was then analysed using P450-GloMax 96 microplate luminometer. Lentivirus production and transduction of human embryonic stem cells
  • the EF1 a-GFP lentivector was constructed and produced by Vectalys (Toulouse, France).
  • the APOA-II-GFP lentivector was constructed in the laboratory and produced by Vectalys.
  • hESCs Prior transduction with lentiviruses, hESCs were dissociated and were incubated with viral particles for 3 hours at 37 ⁇ C in low-attachment 24-well plate (Corning Life Sciences) under gentle rocking before seeding onto mitotically inactivated MEF in hESC medium containing 4 ng/ml FGF2 (R&D systems). Undifferentiated transduced cells were expanded and differentiated using chemically defined conditions described above.
  • DE cells were generated by culturing H9 cells or hIPSCs for 2 days in CDM + 10 ng/ml Activin + FGF2 12 ng/ml, and for 3 days in CDM-PVA, 100 ng/ml Activin, 20 ng/ml FGF2, 10 ng/ml BMP4, 10 ⁇ LY294002.
  • HNF4alpha and alpha-Fetoprotein two markers expressed in hepatic progenitors during the early stages of liver development.
  • AFP alpha-Fetoprotein
  • hepatic progenitors generated by the combination of FGF10, RA and SB431542 expressed EpCAM.
  • HNF4a and AFP or CK19 were co-expressed in 60% and 50% of the cells respectively. Since during liver development hepatocytes and biliary epithelial cells derive from a common bipotential progenitor (hepatoblasts), our results suggest that a population of hepatoblasts has been generated during the differentiation process.
  • AAT Apolipoprotein A-ll
  • ApoAII Apolipoprotein A-ll
  • Tyrosine Aminotransferase tryptophan 2,3-dioxygenase
  • Factor IX the detoxifying enzymes Cyp3A7 and Cyp7A1 as compared with human fetal and adult hepatocytes.
  • hepatocytes were confirmed by immunostaining analyses showing that differentiating hepatic progenitors expressed near homogeneously CK8/18 and that clusters of cells expressed AAT and high level of Albumin (Alb). FACS analyses showed that 35% of the cells expressed ASGR1 , LDLR, c-met and alpha6 integrin. Interestingly, these two last cell surface markers are hallmarks of proliferating hepatic cells in vivo.
  • ES-derived hepatic cells are functional In vivo
  • hepatocytes generated from hESCs were differentiated for 21 days and the resulting cells were transplanted into the liver uPAxrag2 gammac /_ mice.
  • These immunodeficient transgenic mice express the urokinase gene under the control of Alb promoter. This transgene is toxic for hepatocytes and thus it blocks transiently liver growth (until transgene is inactivated in resident cells), allowing a better engraftment of the transplanted cells.
  • Immunohistochemical analyses showed the presence of cells expressing human AAT and ALB in the liver of transplanted mice confirming that hepatic cells generated from hESCs were capable to engraft in vivo and to express proteins characteristics of hepatocytes.
  • Human cells were distributed throughout the liver mainly as small and large cell clusters, suggesting that transplanted cells had proliferated and participated in liver growth.
  • human AAT and GFP protein were co-expressed in the same cells confirming the human origin of these cell clusters.
  • the serum of transplanted animals contained 3ng/ml human albumin confirming that the transplanted cells displayed in vivo some functions characteristics of hepatocytes.
  • Human induced pluripotent stem cells can be derived from reprogrammed fibroblasts. Therefore, we investigated whether the culture conditions developed to generate hepatocytes from hESCs could also be efficient in differentiating hIPSCs into hepatic cells.
  • Foreskin fibroblast were reprogrammed in CDM + Activin A + FGF2 as described (Vallier et al., 2009) using retrovirus expressing Oct-4, Sox2, KLF4, and cMyc and three of the resulting hIPSCs lines were grown in the culture conditions described above. Immunostaining and Q-PCR analyses showed that the cells generated under these culture conditions expressed HNF4a, AFP, and Albumin at similar level than hESCs differentiated using the same culture conditions. All together, these data suggest that our approach developed with hESCs can be used to generate liver cells from hIPSCs.
  • hESCs are differentiated into DE cells using combination of high dose of Activin A, FGF2, BMP4 and Ly294002.
  • Activin A Activin A
  • FGF2 FGF2, BMP4
  • Ly294002 Ly294002
  • the use of this PI3 kinase inhibitor to increase endoderm differentiation of hESCs has been shown previously (Johansson and Wiles, 1995). However, this study was based on media containing serum, matrigel and feeders. In addition, inhibition of PI3 kinase in our conditions was not sufficient to block the effect of Activin signalling on pluripotency.
  • liver bud specification takes 3-4 days in human against 12-24 hours in the mouse and thus, mechanisms happening very quickly during mouse development could become more evident during differentiation of hESCs in vitro.
  • the third step consists in differentiating these hepatic progenitors into hepatocytes while maintaining a proliferative status using a combination of growth factors (FGF4, EGF and HGF) known to be involved in this process in vivo (Jung et al., 1999; Suzuki et al., 2003).
  • FGF4, EGF and HGF growth factors
  • the cells generated expressed various adult liver-specific proteins, as well as key hepatocyte nuclear factors required for controlling the expression of many liver-specific genes. In addition these cells also exhibited specific function of liver cells.
  • hepatocytes retain some immature characteristics such as expression of AFP as already reported by others (Basma et al., 2009; Cai et al., 2007). Further investigations will be required to determine conditions for generating fully mature hepatocytes. Additional inducing factors in combination with high-cell-density culture or co-culture with other cell types such as endothelial cells might represent a potential solution to overcome this major challenge.
  • hES-derived cells Tumor formation and abnormal growth remain another major issue when using hES-derived cells in vivo. Indeed, generated populations can be easily contaminated by undifferentiated pluripotent cells which have the capacity to form teratomas (D'Amour et al., 2006; Kroon et al., 2008). In addition, adult environment might not be capable to control the proliferative capacity of early progenitors leading to uncontrolled proliferation. Thus, it was recently reported that hESC-derived AFP-producing cells induced teratomas formation (Ishii et al., 2007). Adenocarcinomas were also observed intraperitoneal ⁇ in analbuminemic rats transplanted with hESC-derived hepatocytes (Basma et al., 2009). Importantly, hepatic cells generated using our three-step approach did not produce tumors after transplantation, suggesting that our method induces differentiation of the totality of pluripotent cells.
  • mice models will not allow by themselves to determine whether differentiated cells will be safe for clinical applications. Indeed, the quantity of cells transplanted is limited by the size of the organs and studies on large animals such as nonhuman primates will be needed to carefully address safety issues.
  • Fibroblast growth factor 10 is critical for liver growth during embryogenesis and controls hepatoblast survival via beta-catenin activation. Hepatology 46,1 187-1 197.
  • MIAMI Marrow-isolated adult multilineage inducible
  • Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat Cell Biol 9, 255-267.
  • RAR and RXR selective ligands cooperatively induce apoptosis and neuronal differentiation in P19 embryonal carcinoma cells. FASEB J 10, 1071 -1077.
  • SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62, 65-74.
  • ALK transforming growth factor-beta superfamily type I activin receptor-like kinase
  • Dimethyl sulfoxide has an impact on epigenetic profile in mouse embryoid body. Stem Cells 24, 2549-2556.
  • Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol 26, 443-452.
  • mice Michieli, P., Cavassa, S., Basilico, C, De Luca, A., Mazzone, M., Asti, C, Chiusaroli, R., Guglielmi, M., Bossu, P., Colotta, R, et al. (2002).
  • An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity. Nat Biotechnol 20, 488-495.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP10782300A 2009-11-25 2010-11-25 Verfahren zur hepatischen differenzierung von definitiven entodermzellen Withdrawn EP2504424A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10782300A EP2504424A1 (de) 2009-11-25 2010-11-25 Verfahren zur hepatischen differenzierung von definitiven entodermzellen

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09306136 2009-11-25
EP10782300A EP2504424A1 (de) 2009-11-25 2010-11-25 Verfahren zur hepatischen differenzierung von definitiven entodermzellen
PCT/EP2010/068237 WO2011064309A1 (en) 2009-11-25 2010-11-25 Method for hepatic differentiation of definitive endoderm cells

Publications (1)

Publication Number Publication Date
EP2504424A1 true EP2504424A1 (de) 2012-10-03

Family

ID=41631085

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10782300A Withdrawn EP2504424A1 (de) 2009-11-25 2010-11-25 Verfahren zur hepatischen differenzierung von definitiven entodermzellen

Country Status (4)

Country Link
US (1) US20130031645A1 (de)
EP (1) EP2504424A1 (de)
JP (1) JP2013511969A (de)
WO (1) WO2011064309A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
JP6301316B2 (ja) * 2012-05-23 2018-03-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 内胚葉細胞および肝実質細胞の組成物ならびにそれらの細胞を入手および使用する方法
JP6232638B2 (ja) * 2013-06-24 2017-11-22 国立研究開発法人医薬基盤・健康・栄養研究所 肝前駆細胞増殖用培地
CN106661548B (zh) 2014-05-28 2020-12-11 儿童医院医疗中心 用于经由定向分化将前体细胞转化为胃组织的方法和系统
JP6804438B2 (ja) 2014-10-17 2020-12-23 チルドレンズ ホスピタル メディカル センター 多能性幹細胞を使用するヒト小腸のｉｎ ｖｉｖｏモデル、並びにそれを作製、及び使用する方法
GB201510950D0 (en) * 2015-06-22 2015-08-05 Cambridge Entpr Ltd In vitro Production of Cholangiocytes
ES2929758T3 (es) 2016-05-05 2022-12-01 Childrens Hospital Med Ct Métodos para la fabricación in vitro de tejido del fondo gástrico y composiciones relacionadas con el mismo
KR102729404B1 (ko) 2016-11-04 2024-11-14 칠드런즈 호스피탈 메디칼 센터 간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
JP7068305B2 (ja) 2016-12-05 2022-05-16 チルドレンズ ホスピタル メディカル センター 結腸オルガノイドならびにその作製方法および使用方法
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US12281334B2 (en) 2017-04-14 2025-04-22 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
AU2018279790B2 (en) * 2017-06-09 2022-04-07 Children's Hospital Medical Center Liver organoid compositions and methods of making and using same
EP3694603B1 (de) 2017-10-10 2026-04-08 Children's Hospital Medical Center Ösophagusgewebe- und/oder organoidzusammensetzungen und verfahren zu ihrer herstellung
US12379372B2 (en) 2017-12-21 2025-08-05 Children's Hospital Medical Center Digitalized human organoids and methods of using same
CN108611315B (zh) * 2018-03-14 2022-02-15 北京平安普德生物技术有限公司 诱导人胚胎干细胞定向分化为肝样组织的培养基及诱导方法和应用
KR102887406B1 (ko) 2018-07-26 2025-11-19 칠드런즈 호스피탈 메디칼 센터 간-담도-췌장 조직 및 이를 제조하는 방법
AU2019339410A1 (en) 2018-09-12 2021-04-15 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
CN109251884A (zh) * 2018-10-09 2019-01-22 刘卫辉 一种三步法序贯式诱导胎肝干细胞向成熟肝细胞分化的方法
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
CN113728090B (zh) * 2019-04-08 2024-04-05 诺和诺德股份有限公司 从干细胞衍生的定形内胚层生成胰腺内胚层
WO2020243613A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
WO2020243633A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Shaped organoid compositions and methods of making same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009809A1 (en) * 1992-10-30 1994-05-11 Genentech, Inc. Method for preventing or treating liver disease
IL127558A0 (en) 1996-07-03 1999-10-28 Genentech Inc Hepatocyte growth factor receptor agonists and uses thereof
AUPP380498A0 (en) 1998-05-29 1998-06-25 Biomolecular Research Institute Limited Egf receptor agonists and antagonists
EP1401282A4 (de) * 2001-05-25 2005-03-30 Cythera Inc Stammzellendifferenzierung
AU2007254766A1 (en) * 2006-06-02 2007-12-13 University Of Georgia Research Foundation, Inc. Pancreatic and liver endoderm cells and tissue by differentiation of definitive endoderm cells obtained from human embryonic stems
GB0622394D0 (en) 2006-11-09 2006-12-20 Univ Cambridge Tech Differentiation of pluripotent cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011064309A1 *

Also Published As

Publication number Publication date
US20130031645A1 (en) 2013-01-31
JP2013511969A (ja) 2013-04-11
WO2011064309A1 (en) 2011-06-03

Similar Documents

Publication Publication Date Title
US20130031645A1 (en) Method for hepatic differentiation of definitive endoderm cells
Touboul et al. Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development
US20240150721A1 (en) Use of a Laminin for Differentiating Pluripotent Cells into Hepatocyte Lineage Cells
JP6893527B2 (ja) ＳＣ−β細胞及び組成物並びにその生成方法
AU2014218290B2 (en) Methods for generating hepatocytes and cholangiocytes from pluripotent stem cells
Sancho-Bru et al. Directed differentiation of murine-induced pluripotent stem cells to functional hepatocyte-like cells
US9777258B2 (en) Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the method, and methods for using the cells
JP2018508207A5 (de)
JP2011526784A (ja) 多能性幹細胞の分化
US20120100115A1 (en) Regionalised endoderm cells and uses thereof
CA2986830C (en) Use of a laminin for differentiating pluripotent cells into hepatocyte lineage cells
HK40026459A (en) Use of a laminin for differentiating pluripotent cells into hepatocyte lineage cells
Alsagheir Differentiation of human embryonic stem cells into hepatocytes and their in vivo application for hepatitis C viral production
NZ750694B2 (en) Methods for generating hepatocytes and cholangiocytes from pluripotent stem cells
NZ750694A (en) Methods for generating hepatocytes and cholangiocytes from pluripotent stem cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120622

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140124

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140603